Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$86.83 USD

86.83
881,443

-0.46 (-0.53%)

Updated Jun 17, 2024 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Q4 Earnings Top, Margins Increase

by Zacks Equity Research

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe.

Edwards Lifesciences (EW) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Edwards Lifesciences (EW) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 4.92% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

HOLX vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe

by Zacks Equity Research

Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.

Here's How Much You'd Have If You Invested $1000 in Edwards Lifesciences a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

by Zacks Equity Research

Strong adoption of the MITRIS RESILIA valve and increased demand for the HemoSphere monitoring platform will likely drive Edwards Lifesciences' (EW) Q4 revenues.

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Here's Why You Should Retain Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW), led by strong underlying growth across all product groups.

Edwards Lifesciences (EW) Rides on Innovation Amid Rising Costs

by Zacks Equity Research

Edwards Lifesciences (EW) expects to report underlying sales growth in the mid-single-digit range for 2022, banking on market growth and the adoption of premium technologies.

Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.

Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise

by Zacks Equity Research

Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.

Edwards Lifesciences (EW) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.61% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intuitive Surgical, Inc. (ISRG) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 8.18% and 2.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

by Zacks Equity Research

Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.

Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues

by Zacks Equity Research

Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.

Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve

by Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.

Edward Lifesciences (EW) Gains From New Products Amid Cost Woe

by Zacks Equity Research

Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.

    OCPNY or EW: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    OCPNY vs. EW: Which Stock Is the Better Value Option?

    Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision

    by Zacks Equity Research

    Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.

    Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up

    by Zacks Equity Research

    Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.

    Edwards Lifesciences (EW) Matches Q2 Earnings Estimates

    by Zacks Equity Research

    Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?